应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02228 晶泰控股
休市中 11-20 16:08:29
4.800
-0.430
-8.22%
最高
5.090
最低
4.730
成交量
6,340万
今开
5.090
昨收
5.230
日振幅
6.88%
总市值
206.26亿
流通市值
206.26亿
总股本
42.97亿
成交额
3.08亿
换手率
1.48%
流通股本
42.97亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
医药股受压 恒生生物科技指数、恒生医疗保健指数双双走低
金吾财讯 · 11-20 11:01
医药股受压 恒生生物科技指数、恒生医疗保健指数双双走低
异动解读|晶泰控股盘中下跌4.02%,MSCI指数调整继续压制短线情绪
行情直击 · 11-20 09:41
异动解读|晶泰控股盘中下跌4.02%,MSCI指数调整继续压制短线情绪
异动解读|晶泰控股盘中下跌4.64%,MSCI指数调整继续压制短线情绪
行情直击 · 11-19
异动解读|晶泰控股盘中下跌4.64%,MSCI指数调整继续压制短线情绪
异动解读|晶泰控股盘中下跌4.43%,MSCI指数调整继续压制短线情绪
行情直击 · 11-17
异动解读|晶泰控股盘中下跌4.43%,MSCI指数调整继续压制短线情绪
异动解读|晶泰控股盘中下跌4.34%,MSCI指数调整继续压制短线情绪
行情直击 · 11-16
异动解读|晶泰控股盘中下跌4.34%,MSCI指数调整继续压制短线情绪
【券商聚焦】中信建投:医疗器械与服务行业三季度业绩持续改善,板块性机会逐渐显现
金吾财讯 · 11-16
【券商聚焦】中信建投:医疗器械与服务行业三季度业绩持续改善,板块性机会逐渐显现
晶泰科技发布“科学家”计划:开放真实产业命题,招募全球青年科研团队
新浪科技 · 11-14
晶泰科技发布“科学家”计划:开放真实产业命题,招募全球青年科研团队
晶泰控股(02228)MSCI指数调整背后:被动资金冲击有限 AI4S商业化仍是核心看点
智通财经 · 11-13
晶泰控股(02228)MSCI指数调整背后:被动资金冲击有限 AI4S商业化仍是核心看点
CXO板块受压下行 同源康医药-B(02410)跌4.39% 机构指板块三季报后板块进入业绩真空期
金吾财讯 · 11-13
CXO板块受压下行 同源康医药-B(02410)跌4.39% 机构指板块三季报后板块进入业绩真空期
异动解读|晶泰控股盘中下跌4.24%,遭MSCI中国指数剔除
行情直击 · 11-12
异动解读|晶泰控股盘中下跌4.24%,遭MSCI中国指数剔除
晶泰控股(02228)涨4.08% 携手Laboratoires Pierre Fabre布局肿瘤、罕见病小分子新药
金吾财讯 · 11-09
晶泰控股(02228)涨4.08% 携手Laboratoires Pierre Fabre布局肿瘤、罕见病小分子新药
【港股开盘】港股开盘向好 恒指高开0.59% 药明生物(02269)涨2.90%
金吾财讯 · 11-09
【港股开盘】港股开盘向好 恒指高开0.59% 药明生物(02269)涨2.90%
港股异动 | 晶泰控股(02228.HK)高开逾5% 与皮尔法伯集团达成一项AI驱动药物发现合作
智通财经 · 11-09
港股异动 | 晶泰控股(02228.HK)高开逾5% 与皮尔法伯集团达成一项AI驱动药物发现合作
晶泰控股:与皮尔法伯开展人工智能驱动药物发现合作
南方财经网 · 11-09
晶泰控股:与皮尔法伯开展人工智能驱动药物发现合作
晶泰控股(02228.HK)与LABORATOIRES PIERRE FABRE开展AI驱动药物发现合作
智通财经 · 11-09
晶泰控股(02228.HK)与LABORATOIRES PIERRE FABRE开展AI驱动药物发现合作
晶泰控股(02228)携手法国皮尔法伯实验室推进AI驱动抗肿瘤新药研发
公告速递 · 11-09
晶泰控股(02228)携手法国皮尔法伯实验室推进AI驱动抗肿瘤新药研发
异动解读|晶泰控股盘中下跌5.02%,板块走弱叠加股份变动披露
行情直击 · 11-06
异动解读|晶泰控股盘中下跌5.02%,板块走弱叠加股份变动披露
异动解读|晶泰控股开盘下跌5.26%,板块走弱叠加股份变动披露
行情直击 · 11-06
异动解读|晶泰控股开盘下跌5.26%,板块走弱叠加股份变动披露
晶泰控股更新2026年10月股份变动月报表,已发行股本减少465.7万股
公告速递 · 11-05
晶泰控股更新2026年10月股份变动月报表,已发行股本减少465.7万股
异动解读|晶泰控股盘中下跌5.07%,报5.81港元
行情直击 · 11-02
异动解读|晶泰控股盘中下跌5.07%,报5.81港元
加载更多
公司概况
公司名称:
晶泰控股
所属市场:
SEHK
上市日期:
--
主营业务:
晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司。该公司主要经营两个业务。药物发现解决方案业务主要包括早期苗头化合物生成到研究性新药的开发阶段,为临床试验的启动提供研究。智能机器人解决方案主要包括固态研发服务及自动化化学合成服务等。该公司在国内和国外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02228","market":"HK","secType":"STK","nameCN":"晶泰控股","latestPrice":4.8,"timestamp":1795162109003,"preClose":5.23,"halted":0,"volume":63396000,"delay":0,"changeRate":-0.08221797323135766,"floatShares":4297000000,"shares":4297000000,"eps":0.03,"marketStatus":"休市中","change":-0.43,"latestTime":"11-20 16:08:29","open":5.09,"high":5.09,"low":4.73,"amount":308053745,"amplitude":0.068834,"askPrice":4.8,"askSize":134000,"bidPrice":4.78,"bidSize":41000,"shortable":3,"etf":0,"ttmEps":-0.057,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":7,"adr":0,"listingDate":1718208000000,"exchange":"SEHK","adjPreClose":5.23,"openAndCloseTimeList":[[1795138200000,1795147200000],[1795150800000,1795161600000]],"volumeRatio":1.6520901943013833,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"TPX.HK","impliedVol":0.568,"impliedVolPercentile":0.2456},"requestUrl":"/m/hq/s/02228","defaultTab":"news","newsList":[{"id":"2684418223","title":"医药股受压 恒生生物科技指数、恒生医疗保健指数双双走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2684418223","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684418223?lang=zh_cn&edition=full","pubTime":"2026-11-20 11:01","pubTimestamp":1795143678,"startTime":"0","endTime":"0","summary":"详细来看,恒生生物科技指数跌4.08%,其中英硅智能跌7.05%,金斯瑞生物科技跌6.83%,康方生物跌6.64%,药明生物跌6.34%,晶泰控股跌5.83%,映恩生物-B跌5.49%,亚盛医药跌4.79%,药明合联跌4.98%,德适-B跌4.55%。恒生医疗保健指数跌3.8%,其中剂泰科技-P跌7.62%,科济药业-B跌7.43%,宝济药业-B跌7.15%,英硅智能跌7.05%,荣昌生物跌6.86%,康方生物跌6.72%,金斯瑞生物科技跌6.50%,药明生物跌6.25%,和铂医药-B跌5.83%。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1996488","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU0211977185.USD","02659","LU2488822045.USD","LU0456846285.SGD","LU1328277881.USD","LU1813983027.USD","02228","SG9999011746.SGD","09939","LU1688375341.USD","BK1100","03696","IE00BFMHRM44.USD","09995","LU0029874905.USD","LU0039217434.USD","LU0326950275.SGD","LU0572944931.SGD","BK1161","02269","02171","LU0348783233.USD","02268","LU0327786744.USD","02526","LU0588546209.SGD","06855","LU0516422440.USD","LU0229945570.USD","02142","HK0000306701.USD","159938","09926","07666","SG9999002562.SGD","LU0516423174.USD","01548","HK0000320223.HKD","LU0516422952.EUR","BK1610","LU0140636845.USD","LU0516423091.SGD","HK0000252152.HKD","09606","LU0417516902.SGD","LU0320764243.SGD","159506","LU1242518931.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1135702780","title":"异动解读|晶泰控股盘中下跌4.02%,MSCI指数调整继续压制短线情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1135702780","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135702780?lang=zh_cn&edition=full","pubTime":"2026-11-20 09:41","pubTimestamp":1795138915,"startTime":"0","endTime":"0","summary":"11月20日,晶泰控股盘中下跌4.02%,报4.985港元,成交额2835.61万港元。消息面上,市场仍在消化公司将于11月30日收市后从MSCI中国指数转入MSCI全球小型股指数的影响,投资者对被动资金流向及外资持仓变化的担忧继续压制短线情绪。已披露信息显示,此次调整属于MSCI指数体系内部的市值分层变化,并非被完全剔除,理论上被动资金冲击或相对有限;但在当前交易时段内,指数调整仍是更直接的股价压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"晶泰控股盘中下跌,指数调整压制情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192267609","title":"异动解读|晶泰控股盘中下跌4.64%,MSCI指数调整继续压制短线情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1192267609","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192267609?lang=zh_cn&edition=full","pubTime":"2026-11-19 11:09","pubTimestamp":1795057781,"startTime":"0","endTime":"0","summary":"11月19日,晶泰控股盘中下跌4.64%,报5.14港元,成交额5759.28万港元。消息面上,市场仍在消化公司将于11月30日收市后从MSCI中国指数转入MSCI全球小型股指数的影响,投资者对被动资金流向及外资持仓变化的担忧继续压制短线情绪。从已披露信息看,此次调整属于MSCI指数体系内部的市值分层变化,并非被完全剔除,理论上被动资金冲击或相对有限;但在当前交易时段内,指数调整仍是更直接的股价压力。此前公司与Pierre Fabre达成AI驱动药物发现合作,短期未能对冲情绪面扰动。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"晶泰控股盘中下跌,MSCI调整压制情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130803822","title":"异动解读|晶泰控股盘中下跌4.43%,MSCI指数调整继续压制短线情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1130803822","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130803822?lang=zh_cn&edition=full","pubTime":"2026-11-17 10:13","pubTimestamp":1794881614,"startTime":"0","endTime":"0","summary":"11月17日,晶泰控股盘中下跌4.43%,报5.28港元,成交额6512.87万港元。消息面上,市场仍在消化公司将于11月30日收市后从MSCI中国指数转入MSCI全球小型股指数的影响,投资者对被动资金流向及外资持仓变化的担忧继续压制短线情绪。从已披露信息看,此次调整属于MSCI指数体系内部的市值分层变化,并非被完全剔除,理论上被动资金冲击或相对有限;但在当前交易时段内,指数调整仍是更直接的股价压力。此前公司与Pierre Fabre达成AI驱动药物发现合作,短期未能对冲情绪面扰动。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"晶泰控股盘中下跌,MSCI调整压制情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132857909","title":"异动解读|晶泰控股盘中下跌4.34%,MSCI指数调整继续压制短线情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1132857909","media":"行情直击","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132857909?lang=zh_cn&edition=full","pubTime":"2026-11-16 09:44","pubTimestamp":1794793470,"startTime":"0","endTime":"0","summary":"11月16日,晶泰控股盘中下跌4.34%,报5.605港元,成交额5150.2万港元。消息面上,此前MSCI公布季检结果,公司将于11月30日收市后从MSCI中国指数转入MSCI全球小型股指数,市场对被动资金流向及外资持仓变化的担忧仍在发酵,成为短线股价承压的更直接催化。尽管公司日前还宣布与Pierre Fabre开展AI驱动药物发现合作,涉及肿瘤及潜在皮肤病、罕见病项目,但当前交易时段内,指数调整对情绪面的影响更为明显。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"晶泰控股异动下跌,MSCI调整压制情绪","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683466544","title":"【券商聚焦】中信建投:医疗器械与服务行业三季度业绩持续改善,板块性机会逐渐显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2683466544","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683466544?lang=zh_cn&edition=full","pubTime":"2026-11-16 08:45","pubTimestamp":1794789914,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指,Q3多家公司业绩超预期、27年有望业绩改善,板块效应将逐步体现。随着政策影响逐步出清,企业战略调整后业绩逐步复苏,器械板块正在迎来估值、业绩双修复。重点关注2027年业绩增长及持续改善的公司,未来有望实现业绩估值双击。预计多个高值耗材和IVD板块的集采及降价政策影响将于年底或明年初逐步出清,板块性投资机会逐步凸显。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1996048","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","01530","159883","LU1251922891.USD","MDEV","LU1719994722.HKD","03933","LU2328871848.SGD","09926","09996","LU0307460666.USD","02196","02268","IE00B3M56506.USD","LNGR","MEDX","HART","LU2476274308.USD","01789","AGNG","IEIH","LU0348825331.USD","LU1720050803.USD","RSPH","01099","KCE","LU0348766576.USD","PTH","LU1961090484.USD","02228","LU1188198961.HKD","LU2399975544.HKD","BK1583","09688","BK1574","BK1161","LU0348784397.USD","LU0417516738.SGD","LU1770034418.SGD","LU2476274720.SGD","KURE","601066","GDOC","LU0417516902.SGD","LU2488822045.USD","BK1515","02367","06821","LU0463099449.HKD","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683680169","title":"晶泰科技发布“科学家”计划:开放真实产业命题,招募全球青年科研团队","url":"https://stock-news.laohu8.com/highlight/detail?id=2683680169","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683680169?lang=zh_cn&edition=full","pubTime":"2026-11-14 15:14","pubTimestamp":1794640440,"startTime":"0","endTime":"0","summary":"新浪科技讯 11月14日下午消息,今日晶泰科技发布“科学家”计划,面向全球青年科研团队开放真实产业课题,搭建从科研创意、实验验证到成果落地的通道,同日启用全新的北京创新中心。“今天发布的科学家计划,正是希望基于我们走过的路、踩过的坑,力所能及地为怀揣创新想法的青年科研力量撑一把伞。”","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-11-14/doc-iniysvmc2870404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1617","02228","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683820528","title":"晶泰控股(02228)MSCI指数调整背后:被动资金冲击有限 AI4S商业化仍是核心看点","url":"https://stock-news.laohu8.com/highlight/detail?id=2683820528","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683820528?lang=zh_cn&edition=full","pubTime":"2026-11-13 11:25","pubTimestamp":1794540337,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,国际指数编制公司MSCI于11月11日公布最新指数审议结果,晶泰控股从MSCI中国指数转入MSCI全球小型股指数,相关调整将于11月30日收市后正式生效。此次调整引发市场对晶泰控股外资持仓及被动资金流向的关注。晶泰控股仍保留在MSCI相关指数体系中,只是所属指数层级发生变化。总体而言,此次MSCI调整更多是指数体系内部的市值规模分层变化,而非对晶泰控股长期成长价值的否定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1522729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","02228","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683478435","title":"CXO板块受压下行 同源康医药-B(02410)跌4.39% 机构指板块三季报后板块进入业绩真空期","url":"https://stock-news.laohu8.com/highlight/detail?id=2683478435","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683478435?lang=zh_cn&edition=full","pubTime":"2026-11-13 10:09","pubTimestamp":1794535784,"startTime":"0","endTime":"0","summary":"方正证券表示,由“CXO的核心大药”转向“龙头CXO与平台型Pharma”并重。5月以来该机构推荐CXO,逻辑是中国核心大药的核心供应商,这一判断本身并未被证伪;但三季报后板块进入业绩真空期,单一方向的性价比下降。更新后,CXO是底仓,收益来自全球产能转移与订单能见度;平台型 Pharma是弹性,收益来自BD兑现与里程碑分成,定价基准从“单品峰值销售”切换为“平台可持续签单”。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995966","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","02410","159938","BK1588","LU0307460666.USD","LU0828237510.HKD","LU0588546209.SGD","LU1770034418.SGD","BK1500","09606","LU2543165471.USD","03759","BK1141","LU1969619763.USD","02315","WX","HK0000500386.USD","LU2328871848.SGD","06160","KURE","LU1719994722.HKD","06127","BK1574","BK1583","02228","06821","BK1576","BK1617","CXO","LU1251922891.USD","BK1191","LU0228659784.USD","BK1515","HK0000252152.HKD","LU1303224171.USD","01167","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187992424","title":"异动解读|晶泰控股盘中下跌4.24%,遭MSCI中国指数剔除","url":"https://stock-news.laohu8.com/highlight/detail?id=1187992424","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187992424?lang=zh_cn&edition=full","pubTime":"2026-11-12 13:54","pubTimestamp":1794462885,"startTime":"0","endTime":"0","summary":"11月12日,晶泰控股盘中下跌4.24%,报6.095港元,成交额1.58亿港元。消息面上,MSCI公布季检结果,晶泰控股被剔出MSCI中国指数,相关调整将于11月30日收市后生效。指数调整通常会影响被动资金配置预期,成为股价短线承压的直接催化。此前公司曾公告与Pierre Fabre开展AI驱动药物发现合作,覆盖肿瘤、皮肤病及罕见病领域,但当日盘中更直接的扰动来自指数剔除消息。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"晶泰控股遭MSCI剔除,盘中异动下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682609827","title":"晶泰控股(02228)涨4.08% 携手Laboratoires Pierre Fabre布局肿瘤、罕见病小分子新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2682609827","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682609827?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:36","pubTimestamp":1794188199,"startTime":"0","endTime":"0","summary":"消息面上,公司公布,公司两家全资附属公司QuantumPharm Limited及晶泰智药技术(上海),与Laboratoires Pierre Fabre集团成员公司Pierre Fabre Médicament SAS订立研究合作协议,据此,集团与Laboratoires Pierre Fabre将于肿瘤学领域的多个研究项目开展新型临床候选药物发现合作,并可能涵盖皮肤病学及罕见病领域。Laboratoires Pierre Fabre将贡献其于疾病生物学、药物发现、转化研究及临床开发方面之专业知识,以选出及推进最具前景的化合物,并将负责后续临床及商业开发。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995483","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228","BK1617","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682074822","title":"【港股开盘】港股开盘向好 恒指高开0.59% 药明生物(02269)涨2.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682074822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682074822?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:25","pubTimestamp":1794187555,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘向好,恒指高开0.59%,国企指数高开0.62%,恒生科技指数高开1.02%。中国生物制药高开1.96%,公司公布,附属公司正大天晴自主研发的国家1类创新药TQ-A3334“TLR7激动剂”,已于2026年美国肝病研究学会年会的最新突破性摘要平行专场,以口头报告形式公布II期临床研究结果。TQ-A3334在既往临床研究中已显示出良好的安全性和初步抗乙型肝炎病毒活性。内地股市上周五走势向下,沪综指低开低走,收市下跌1.1%,沪深两市成交额亦明显减少。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MTYwMGM1ZDEwYjRjZDY4ZmI3MTk0ZDEyM2Y1MWFkMjMxODA4Mzk0Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995477","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU1961090484.USD","LU0348827113.USD","MCHmain","LU0307460666.USD","07300","01177","LU0516423174.USD","03037","LU0314109678.HKD","LU0516423091.SGD","03419","LU0561508036.HKD","LU1242518857.USD","LU0320764243.SGD","LU0326950275.SGD","LU0634319403.HKD","LU2476274720.SGD","BK1610","BK1617","LU0229945570.USD","LU0211977185.USD","SG9999002562.SGD","LU0128526141.USD","LU0417516738.SGD","IE00BZ08YS42.EUR","LU0516422440.USD","IE00B0JY6N72.USD","LU0320764599.SGD","HK0000165453.HKD","83115","BK1521","02228","LU0051755006.USD","513600","03115","HHImain","LU2476274308.USD","LU1328277881.USD","LU2778985437.USD","BK1515","LU1880383366.USD","LU0543330566.HKD","LU0029874061.USD","LU0359201612.USD","LU0823426480.USD","LU0029874905.USD","LU0348735423.USD","82800","02800","LU0456827905.SGD","WXXWY","LU0819121731.USD","LU0417516902.SGD","BK1589","LU0856984785.SGD","LU0359202008.SGD","LU1813983027.USD","LU0128522744.USD","BK1576","02833","LU0043850808.USD","LU0140636845.USD","LU0516422366.SGD","LU0823426308.USD","LU0039217434.USD","LU0979878070.USD","BK1141","LU0572944931.SGD","LU1242518931.SGD","LU0540923850.HKD","LU2399975544.HKD","LU0348825331.USD","LU1794554557.SGD","02269","07200","IE00BFMHRM44.USD","SBHMY","BK1191","SG9999002463.SGD","LU0181495838.USD","LU0516422952.EUR","LU1720050803.USD","LU0327786744.USD","09115","IE00BZ08YT58.USD","KURE","LU0052750758.USD","LU3063872942.SGD","LU0708995153.HKD","07500","SG9999011746.SGD","HSI","LU0708995583.HKD","LU1688375341.USD","LU0456846285.SGD","IE00BZ08YR35.GBP","HSTECH","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682220448","title":"港股异动 | 晶泰控股(02228.HK)高开逾5% 与皮尔法伯集团达成一项AI驱动药物发现合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2682220448","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682220448?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:25","pubTimestamp":1794187552,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1617","02228","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682241508","title":"晶泰控股:与皮尔法伯开展人工智能驱动药物发现合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2682241508","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682241508?lang=zh_cn&edition=full","pubTime":"2026-11-09 08:09","pubTimestamp":1794182977,"startTime":"0","endTime":"0","summary":"南财智讯11月9日电,晶泰控股(02228.HK)发布自愿公告,公司全资附属公司与皮尔法伯集团成员公司皮尔法伯药物公司订立研究合作协议。双方将于肿瘤学领域的多个研究项目开展新型临床候选药物发现合作,并可能涵盖皮肤病学及罕见病领域。根据合作,公司将运用其一体化人工智能能力及机器人平台,针对未公开靶点从头设计并交付新型小分子疗法。合作包括前期付款、多项里程碑付款及后续经济分成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611093925755410.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611093925755410.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FWD","07568","QTOC","161631","OGIG","QDEC","QSWN","TARK","MFIG","QQQM","NJUL","AIFD","SQQQ","AGIX","02228","GK","09086","TQQY","NEWZ","PSQ","QQQ","03455","QLD","AQGX","NOCT","WPAI","QID","PBOT","NAPR","CPNQ","TECY","CHAT","LCLG","QQQX","OVQ","NJAN","NBDS","GPIQ","QMAR","AIBU","KOMP","TQQQ","ARTY","CWC","VUSE","DQJN","QQA","MVPS","AIQU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682824949","title":"晶泰控股(02228.HK)与LABORATOIRES PIERRE FABRE开展AI驱动药物发现合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2682824949","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682824949?lang=zh_cn&edition=full","pubTime":"2026-11-09 08:07","pubTimestamp":1794182856,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","02228","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101852792","title":"晶泰控股(02228)携手法国皮尔法伯实验室推进AI驱动抗肿瘤新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1101852792","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101852792?lang=zh_cn&edition=full","pubTime":"2026-11-09 08:05","pubTimestamp":1794182723,"startTime":"0","endTime":"0","summary":"2026年11月9日,晶泰控股有限公司发布自愿性公告称,其全资附属公司QuantumPharm Limited及晶泰智药技术(上海)有限公司已与Pierre Fabre Médicament SAS签订研究合作协议,双方将在肿瘤学领域的多个研究项目开展新型临床候选药物发现合作,并有可能延伸至皮肤病学及罕见病领域。公告指出,本次合作有望在肿瘤学及其他潜在治疗领域加快高质量临床候选药物的识别,符合晶泰及其股东整体利益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185157462","title":"异动解读|晶泰控股盘中下跌5.02%,板块走弱叠加股份变动披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1185157462","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185157462?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:46","pubTimestamp":1793929591,"startTime":"0","endTime":"0","summary":"11月6日,晶泰控股盘中下跌5.02%,报6.11港元,成交额6616.25万港元。消息面上,生命科学工具和服务板块整体承压,药明生物跌2.63%,金斯瑞生物-一千跌11.52%,药明康德跌2.5%,英矽智能跌7.16%,药明合联跌3.11%,对个股情绪形成拖累。同时,公司近日披露10月股份变动月报,已发行普通股由43.01亿股降至42.97亿股,月内减少465.7万股,主要与此前回购注销股份有关,叠加股份变动信息披露,放大市场观望情绪。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"晶泰控股盘中走低,板块承压叠加股份变动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169141685","title":"异动解读|晶泰控股开盘下跌5.26%,板块走弱叠加股份变动披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1169141685","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169141685?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:23","pubTimestamp":1793928214,"startTime":"0","endTime":"0","summary":"11月6日,晶泰控股开盘下跌5.26%,报6.035港元,成交额391.23万港元。从板块看,生命科学工具和服务个股同步承压,药明生物跌6.7%,英矽智能跌5.54%,药明康德跌3.86%,晶泰控股股价表现亦受行业情绪拖累。晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"晶泰控股开盘走弱,板块承压回购引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156961742","title":"晶泰控股更新2026年10月股份变动月报表,已发行股本减少465.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1156961742","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156961742?lang=zh_cn&edition=full","pubTime":"2026-11-05 06:26","pubTimestamp":1793831173,"startTime":"0","endTime":"0","summary":"2026年11月5日,晶泰控股有限公司公布2026年10月的股份变动月报表。截至2026年10月31日,公司法定股本维持在100,000,000,000股普通股,折合注册资本1,000,000美元。本月内,公司已发行普通股由上月底的4,301,176,179股减少至4,296,519,179股,减少总量为4,657,000股。扣除期初299,000股库存股份后,本月底公司普通股总数为4,296,818,179股。同时,公司披露,旗下多项股份期权和激励计划在本月内合计行使及注销共99,500股股份,并未导致本月新增发行。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132716704","title":"异动解读|晶泰控股盘中下跌5.07%,报5.81港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132716704","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132716704?lang=zh_cn&edition=full","pubTime":"2026-11-02 09:57","pubTimestamp":1793584648,"startTime":"0","endTime":"0","summary":"11月2日,晶泰控股盘中下跌5.07%,报5.81港元,成交额8562.67万港元。晶泰控股所在的生命科学工具和服务行业中,药明康德下跌4.1%,金斯瑞生物-一千下跌3.54%,药明生物下跌3.69%,药明合联下跌4.5%,英矽智能下跌2.67%。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://www.xtalpi.com","stockEarnings":[{"period":"1week","weight":-0.1823},{"period":"1month","weight":-0.2138},{"period":"3month","weight":-0.3774},{"period":"6month","weight":-0.3962},{"period":"1year","weight":-0.5276},{"period":"ytd","weight":-0.4926}],"compareEarnings":[{"period":"1week","weight":-0.0519},{"period":"1month","weight":-0.0525},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.1326},{"period":"ytd","weight":-0.1256}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司。该公司主要经营两个业务。药物发现解决方案业务主要包括早期苗头化合物生成到研究性新药的开发阶段,为临床试验的启动提供研究。智能机器人解决方案主要包括固态研发服务及自动化化学合成服务等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.06643},{"month":2,"riseRate":0.285714,"avgChangeRate":0.016028},{"month":3,"riseRate":0,"avgChangeRate":-0.069153},{"month":4,"riseRate":0.666667,"avgChangeRate":0.048494},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.010585},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.023767},{"month":7,"riseRate":0.428571,"avgChangeRate":0.047576},{"month":8,"riseRate":0.5,"avgChangeRate":-0.032189},{"month":9,"riseRate":0.8,"avgChangeRate":0.065839},{"month":10,"riseRate":0.6,"avgChangeRate":0.092453},{"month":11,"riseRate":0.5,"avgChangeRate":0.05299},{"month":12,"riseRate":0.5,"avgChangeRate":-0.011625}],"exchange":"SEHK","name":"晶泰控股","nameEN":"XTALPI"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"晶泰控股,02228,晶泰控股股票,晶泰控股股票老虎,晶泰控股股票老虎国际,晶泰控股行情,晶泰控股股票行情,晶泰控股股价,晶泰控股股市,晶泰控股股票价格,晶泰控股股票交易,晶泰控股股票购买,晶泰控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}